Osimertinib versus comparator first-generation epidermal growth factor receptor tyrosine kinase inhibitors as first-line treatment in patients with advanced EGFR-mutated non-small cell lung cancer: a Chinese, multicenter, real-world cohort study.
Transl Lung Cancer Res
; 12(11): 2229-2244, 2023 Nov 30.
Article
en En
| MEDLINE
| ID: mdl-38090527
ABSTRACT
Background:
In the phase 3 FLAURA trial, osimertinib was compared with first-generation epidermal growth factor receptor tyrosine kinase inhibitors (EGFR-TKIs) as a first-line treatment for EGFR-mutant non-small cell lung cancer (NSCLC). Osimertinib showed longer progression-free survival (PFS), overall survival (OS), and a similar safety profile. However, more studies demonstrating the effectiveness and safety of osimertinib as a first-line strategy are needed in real-world populations.Methods:
We enrolled 1,556 patients with EGFR-mutated stage IIIc-IV NSCLC from the CAPTRA-Lung database. All patients received either osimertinib (n=202) or a first-generation EGFR-TKI (n=1,354) as their initial treatment. To adjust for differences in baseline characteristics between two groups, 12 propensity score matching (PSM) was performed. Propensity scores included gender, age, Eastern Cooperative Oncology Group performance status score, smoking history, family history of tumor, pathology, EGFR mutations, and central nervous system (CNS) metastases. The standardized mean differences (SMD) before and after PSM were calculated to examine the balance of covariate distributions between two groups.Results:
After PSM, 202 patients receiving osimertinib and 404 patients receiving first-generation EGFR-TKIs were finally identified. SMD of each matched variable is less than 0.10. The median PFS was 19.4 months [95% confidence interval (CI) 14.3-24.4] in the osimertinib arm and 10.9 months (95% CI 9.3-12.5) in the comparator arm [hazard ratio (HR) for progression, 0.47; 95% CI 0.38-0.59; P<0.001). The median OS was 40.5 months (95% CI 27.1-54.0) vs. 34.3 months (95% CI 30.6-38.0) in two groups, respectively (HR for death, 0.76; 95% CI 0.58-1.00; P=0.045). The incidence of grade 3 adverse events (AEs) between the two groups was 1% and 4.2%, respectively. No grade 4 AEs and treatment-related deaths were reported in both groups.Conclusions:
In real-world settings, osimertinib demonstrates longer PFS and OS, with a similar safety profile to that of comparator EGFR-TKIs when used as a first-line strategy in NSCLC patients.
Texto completo:
1
Banco de datos:
MEDLINE
Idioma:
En
Revista:
Transl Lung Cancer Res
Año:
2023
Tipo del documento:
Article
País de afiliación:
China